Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 618 of 5804
-
Brain bleed breakthrough? glue artery to stop return
Disease control Recruiting nowChronic subdural hematomas (CSH) are collections of blood in the subdural space. CSH are becoming the most common cranial neurosurgical condition among adults, and a significant public health problem, due to an increasing use of anticoagulant and antiplatelet medication in an age…
Phase: NA • Sponsor: University Hospital, Brest • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill INX-315 takes on advanced breast and ovarian cancers
Disease control Recruiting nowIncyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor a…
Phase: PHASE1, PHASE2 • Sponsor: Incyclix Bio • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New meningitis vaccine shows promise for infants in landmark trial
⭐️ VACCINE ⭐️ CompletedThis open label randomized study will be conducted to evaluate and/or describe the immunogenicity and describe the safety of MenACYW conjugate vaccine when administered in infants and toddlers. It will be conducted in India and the RSA in 2 cohorts: * Cohort I: Infants and todd…
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:13 UTC
-
Triple threat: new combo tackles resistant lung cancer
Disease control OngoingAMAZE-lung is a multicenter single-arm phase II trial. The protocol treatment consists of amivantamab, lazertinib and bevacizumab (Zirabev®), given in a three-weekly regimen. The primary objective of the trial is to assess the efficacy of amivantamab and bevacizumab added to cont…
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Stent shows promise for brain aneurysm repair
Disease control CompletedThe primary objective of this trial is to evaluate the safety and efficacy of the cerebral flow diverter in the endovascular treatment of wide-necked cerebral aneurysms
Phase: NA • Sponsor: Sinomed Neurovita Technology Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New combo therapy aims to deepen remissions in tough leukemia
Disease control OngoingThis phase II clinical trial tests a chemotherapy regimen (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin with or without rituximab \[DA-EPOCH+/-R\]) with the addition of targeted therapy (tafasitamab) for the treatment of patients with newly d…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New immunotherapy combo takes on tough pancreatic cancer
Disease control CompletedThe goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive chemotherapy while a second…
Phase: PHASE2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill cocktail aims to beat Hard-to-Treat myeloma
Disease control Recruiting nowThe purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New heart device aims to zap away irregular rhythm
Disease control OngoingThe goal of any novel design or therapeutic strategy to treat atrial fibrillation is to restore normal sinus rhythm and to reduce or eliminate the symptoms due to rapid atrial response. Boston Scientific has developed the FARAPULSE™ Pulsed Field Ablation therapy that uses irreve…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New combo aims to outsmart Hard-to-Treat kidney cancer
Disease control OngoingThis phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic).…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could a simple salt save newborn brains? trial tests magnesium for birth asphyxia
Disease control CompletedBirth/Perinatal asphyxia in Pakistan continues to be a leading cause of neonatal mortality and morbidity. It is estimated that around 80 to 120,000 neonates either suffer from or die from birth/perinatal asphyxia every year. In addition to the large number of deaths a larger numb…
Phase: NA • Sponsor: University of Health Sciences Lahore • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New balloon coated with paclitaxel aims to keep brain arteries open
Disease control OngoingThis study is aiming to evaluate the safety and efficacy of SeQuent® Please CIS in the endovascular treatment of symptomatic intracranial atherosclerotic stenosis and restenosis after interventional therapy.
Phase: NA • Sponsor: B. Braun Medical International Trading Company Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Cell therapy trial aims to halt vision loss in dry AMD
Disease control Recruiting nowThis study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless oth…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could a Chemo-Immuno combo boost cancer fight before surgery?
Disease control Recruiting nowThis study is being done because both 5-azacytidine and nivolumab can influence the immune system's response to HPV-associated head and neck cancer, and we wish to evaluate whether taking 5-azacytidine will make HPV-associated head and neck cancer more sensitive to treatment with…
Phase: PHASE2 • Sponsor: Barbara Burtness • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for advanced liver cancer: experimental drug TTI-101 enters Mid-Stage trials
Disease control Recruiting nowThe primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine…
Phase: PHASE1, PHASE2 • Sponsor: Tvardi Therapeutics, Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New eye injection shows promise for blinding swelling condition
Disease control CompletedThis study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New c. diff vaccine shows promise in preventing dangerous diarrhea
⭐️ VACCINE ⭐️ OngoingAn antibody is a substance your body makes to fight off infection. This study will explore the safety and antibody response of a vaccine to prevent severe diarrhea caused by a germ called Clostridoides difficile (C. diff). Three new formulations of the C. diff vaccine will be use…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:24 UTC
-
Could this daily pill slow ALS?
Disease control CompletedThe HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen F will evaluate the safety and efficacy of a single study drug, ABBV-CLS-7262, in participants…
Phase: PHASE2, PHASE3 • Sponsor: Merit E. Cudkowicz, MD • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Sound wave surgery zaps kidney tumors in first human test
Disease control CompletedThe purpose of this trial is to evaluate the technical success and safety profile of the HistoSonics Investigational System for the treatment of primary solid renal tumors.
Phase: NA • Sponsor: HistoSonics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope: drug combo aims to stop brain tumors in breast cancer patients
Disease control OngoingPatients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled. They will receive local therapy with stereotactic radiosurgery ± surgical rese…
Phase: PHASE2 • Sponsor: Carey Anders, M.D. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC